FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Duke ES, Stapleford L, Drezner N, Amatya AK, et al. Clin Cancer Res 2022 Sep 16. pii: 709236. doi: 10.1158/1078-0432.CCR-22-2072.

Read + Share

Amedeo Smart

Independent Medical Education

Duke ES, Stapleford L, Drezner N, Amatya AK, et al. FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clin Cancer Res 2022 Sep 16. pii: 709236. doi: 10.1158/1078-0432.CCR-22-2072.
PMID: 36112541